Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02LCR
|
|||
| Former ID |
DNC001444
|
|||
| Drug Name |
Tiapride
|
|||
| Synonyms |
tiapride; 51012-32-9; Thiapride; Tiapridal; N-(2-(Diethylamino)ethyl)-2-methoxy-5-(methylsulfonyl)benzamide; Tiapridum [INN-Latin]; Tiaprida [INN-Spanish]; UNII-LAH70H9JPH; FLO 1347; Tiapride [INN:BAN:DCF]; Tiapride HCl; EINECS 256-907-9; LAH70H9JPH; BRN 2390588; JTVPZMFULRWINT-UHFFFAOYSA-N; BENZAMIDE, N-(2-(DIETHYLAMINO)ETHYL)-2-METHOXY-5-(METHYLSULFONYL)-; N-(2-(Diethylamino)ethyl)-5-(methylsulfonyl)-o-anisamide; Tiapridum; Tiaprida; Benzamide, N-[2-(diethylamino)ethyl]-2-methoxy-5-(methylsulfonyl)-; NCGC00015996-02; SPI-860
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Alcohol dependence [ICD-11: 6C40.2; ICD-10: F10.2; ICD-9: 303] | Approved | [1] | |
| Neuropathic pain [ICD-11: 8E43.0] | Phase 1 | [2] | ||
| Structure |
 |
Download2D MOL |
||
| Formula |
C15H24N2O4S
|
|||
| Canonical SMILES |
CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC
|
|||
| InChI |
1S/C15H24N2O4S/c1-5-17(6-2)10-9-16-15(18)13-11-12(22(4,19)20)7-8-14(13)21-3/h7-8,11H,5-6,9-10H2,1-4H3,(H,16,18)
|
|||
| InChIKey |
JTVPZMFULRWINT-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 51012-32-9
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
5650056, 8153358, 11111853, 11111854, 11335913, 11361152, 11364248, 11366810, 11369372, 11372631, 11374335, 11377534, 11462124, 11466244, 11467364, 11485038, 11485888, 11489337, 11491371, 11492593, 11495168, 14753076, 24278720, 29224512, 47365211, 47440279, 47662306, 47810769, 47885441, 48035146, 48259255, 48259256, 48416623, 49698930, 49876371, 50100350, 50104277, 57322792, 75320710, 85209867, 85788830, 90340591, 91722395, 92711448, 96025274, 103287107, 104309317, 114916115, 118307518, 124750253
|
|||
| ChEBI ID |
CHEBI:94666
|
|||
| SuperDrug ATC ID |
N05AL03
|
|||
| SuperDrug CAS ID |
cas=051012329
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Dopamine D2 receptor (D2R) | Target Info | Antagonist | [3] |
| Voltage-gated sodium channel alpha Nav1.8 (SCN10A) | Target Info | Inhibitor | [2] | |
| KEGG Pathway | Rap1 signaling pathway | |||
| cAMP signaling pathway | ||||
| Neuroactive ligand-receptor interaction | ||||
| Gap junction | ||||
| Dopaminergic synapse | ||||
| Parkinson's disease | ||||
| Cocaine addiction | ||||
| Alcoholism | ||||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
| Dopamine receptor mediated signaling pathway | ||||
| Nicotine pharmacodynamics pathway | ||||
| Reactome | Interaction between L1 and Ankyrins | |||
| Dopamine receptors | ||||
| G alpha (i) signalling events | ||||
| WikiPathways | Hypothetical Network for Drug Addiction | |||
| Monoamine GPCRs | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| Genes and (Common) Pathways Underlying Drug Addiction | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| Nicotine Activity on Dopaminergic Neurons | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 2 | Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26. | |||
| REF 3 | The treatment of Tourette's syndrome: current opinions. Expert Opin Pharmacother. 2002 Jul;3(7):899-914. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.